ClinicalTrials.gg
CompletedNCT00551538Updated Oct 13, 2010

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

A Phase 4 interventional study of Lispro mix 75/25 and Glargine in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-10-13.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
165th of 175
15 · median 253
Started
2003
with 10 others
Phase 4
103 of 176
2 open now
Registered
38th of 176
by date
Lead sponsor
15 of 176
Eli Lilly and Company

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 165th largest by enrollment of the 175 interventional ones that give a count, is one of 11 that started in 2003, is one of 103 in phase 4, and was the 38th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine if twice-daily Lispro low mixture (75/25) will result in lower post prandial blood glucose readings versus once-daily glargine plus oral diabetic medications.

Read the detailed description

The primary objective of this study is to test the hypothesis that a twice daily insulin regimen consisting of insulin lispro (mix 75/25)plus OAMs will result in a lower 2 hour postprandial plasma glucose, averaged across the morning and evening meals, compared with once daily insulin glargine plus OAMs at bedtime following 12 weeks of treatment.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Diabetes
  • Diabetic
  • Insulin
  • Glargine
  • Lispro
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes
  • Have inadequate overall glycemic control ( greater than or equal to 7.0% and less than or equal to 12.0%) at or within 4 weeks prior to Visit 1
  • Have used:

    • single or multiple OAMs for at least 3 months immediately prior to entering the study, including metformin, sulfonylurea, meglitinides (repaglinide, nateglinide), or alpha glucosidase inhibitors (acarbose, miglitol); or
    • insulin (once or twice daily) for at least 3 months immediately prior to entering the study; or
    • a combination of the above.
  • Are greater than or equal to 21 and less than 80 years of age
  • As determined by the investigator, are capable and willing to:

    • comply with their prescribed diet and medication regimen,
    • perform self blood glucose monitoring,
    • use the patient diary as required for this protocol,
    • participate in two 24 hour inpatient assessments

Exclusion criteria

Exclusion Criteria:

  • Have used a thiazolidinedione (pioglitazone or rosiglitazone) during the 3 months prior to entry into the study
  • Are currently treated with a meglitinide without sulfonylurea
  • Have a known allergy or intolerance to insulin lispro mix 75/25, insulin glargine, or metformin
  • Have plasma creatinine greater than or equal to 1.5 mg/dL (for males) or greater than or equal to 1.4 mg/dL (for females) for patients who will be treated with metformin or; greater than 2 mg/dL for patients treated with other OAMs, as determined by a local laboratory
  • Have received chronic (lasting longer than 2 weeks), systemic therapy (excluding topical and inhaled preparations) within 4 weeks immediately prior to Visit 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Active comparator
    1

    Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.

    Drug: Lispro mix 75/25

  • Active comparator
    2

    Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.

    Drug: Glargine

Interventions

  • DrugLispro mix 75/25

    Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.

  • DrugInsulin GlargineStudies of Insulin GlargineInsulin Glargine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SC injection, once-daily, given in conjunction with oral antidiabetic medications.

06

What researchers measure

Primary outcomes

  1. Combined morning and evening mean 2 hour postprandial plasma glucose during each 24 hour inpatient period.

    Time frame: At end of treatment arm or 3 months.

Secondary outcomes

  1. HbA1c

    Time frame: At end of treatment arm or 3 months.

  2. 2 hour plasma glucose excursions, plasma glucose AUC, and plasma glucose AUC excursions after the three main test meals combined

    Time frame: At end of treatment arm or 3 months.

  3. Plasma glucose AUC excursions during a 24 hours when plasma glucose exceeds the following: greater than or equal to 7.5 mmol/L (135 mg/dL), greater than or equal to 7.8 mmol/L (140 mg/dL), and greater than or equal to 10.0 mmol/L (180 mg/dL)

    Time frame: At end of treatment arm or 3 months.

  4. The number of patients with increased plasma glucose during the last 2 hours of each inpatient period

    Time frame: At end of treatment arm or 3 months.

  5. The mean amplitude of glycemic excursion

    Time frame: At end of treatment arm or 3 months.

  6. Concentration of plasma triglycerides and free fatty acids

    Time frame: At end of treatment arm or 3 months.

  7. Self blood glucose monitoring parameters: fasting, premeal, 2 hour postprandial, 2 hour postprandial excursion, bedtime, and overall daily blood glucose value

    Time frame: At end of treatment arm or 3 months.

  8. Insulin dose and body weight

    Time frame: At end of treatment arm or 3 months.

07

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46202, United States
08

References and documents

Publications

  • Roach P, Malone JK. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes. Diabet Med. 2006 Jul;23(7):743-9. doi: 10.1111/j.1464-5491.2006.01895.x. PubMed 16842478 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2007
First posted
Oct 31, 2007
Start
May 2003
CompletionActual
Dec 2004
Last update
Oct 13, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00551538
First posted
Oct 31, 2007
Start date
May 2003
Completion
Dec 2004
Last update
Oct 13, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion